Evaluation of acute toxicity in the treatment of prostate cancer with conformational radiotherapy

Página do item simplificado
dc.contributor.authorCARLECH, HIGOR S.pt_BR
dc.contributor.authorLISBOA, ANA C.V.C.pt_BR
dc.contributor.authorVITAL, MARCILIO L.pt_BR
dc.contributor.authorZEITUNI, CARLOS A.pt_BR
dc.contributor.authorROSTELATO, MARIA E.C.M.pt_BR
dc.coverageInternacionalpt_BR
dc.creator.eventoINTERNATIONAL NUCLEAR ATLANTIC CONFERENCEpt_BR
dc.date.accessioned2020-01-07T13:20:59Z
dc.date.available2020-01-07T13:20:59Z
dc.date.eventoOctober 21-25, 2019pt_BR
dc.description.abstractBACKGROUND: Radiatiotherapy is often associated with a wide range of significant side effects. These side effects are commonly classified as acute or delayed according to when they manifest in relation to treatment. METHODS: This study aimed to evaluate acute toxicity in patients with prostate cancer treated with conformational radiotherapy (3D) in an Oncology Unit in Eastern Minas Gerais. A prospective, observational, cohort study was performed through a non-probabilistic sampling of convenience, totalazing 45 patients. Patients included in the study were followed from the start of treatment to 3 months after external beam radiation therapy (EBRT). RESULTS: Demographic Characteristics - Of the 45 patients included, mean age was 70.6 ± 8.3 (SD) years, and predominantly white (44.0 %). The majority were married (75.6 %). Considering the risk classification, there was a homogeneous distribution between the low (33.3 %), intermediate (31.1 %) and high (35.6 %) levels. The majority of the patients (57.8 %) had a low risk (T1) classification, followed by intermediate risk classification (33.3%) and high risk (8.9 %). In the Gleason score, 44.4 % presented values below 6 (low), 40.0 % intermediate, and 15.5 % high. 62.2 % had a PSA level less than 10 ng.mL-1, 22.2 % had an intermediate level, from 10 to 20 ng.mL-1 and 15.6%, above 20 ng.mL-1. Manifestation of acute toxicity - It was observed that the majority (59.1 %) of the acute effects manifested during the first consultation, prevailing the symptom of urinary frequency (64.1 %). Regarding the symptoms of acute effects most prevalent during the three consultations, we highlight the urinary frequency with 44.0 %, followed by the urinary residue (20.0 %). CONCLUSION: 80.0 % of the patients presented acute effects during radiotherapy, being the urinary frequency the event more frequent (44.0 %), followed by urinary residue (20.0 %). Eighteen patients (40.0 %) presented only one acute effect and 59.1 % of the effects were observed at the first visit.pt_BR
dc.event.siglaINACpt_BR
dc.format.extent1797-1809pt_BR
dc.identifier.citationCARLECH, HIGOR S.; LISBOA, ANA C.V.C.; VITAL, MARCILIO L.; ZEITUNI, CARLOS A.; ROSTELATO, MARIA E.C.M. Evaluation of acute toxicity in the treatment of prostate cancer with conformational radiotherapy: choort with 45 patients. In: INTERNATIONAL NUCLEAR ATLANTIC CONFERENCE, October 21-25, 2019, Santos, SP. <b>Proceedings...</b> Rio de Janeiro: Associação Brasileira de Energia Nuclear, 2019. p. 1797-1809. Disponível em: http://repositorio.ipen.br/handle/123456789/30584.
dc.identifier.orcid0000-0003-2943-6097pt_BR
dc.identifier.orcid0000-0002-7303-6720pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-2943-6097
dc.identifier.orcidhttps://orcid.org/0000-0002-7303-6720
dc.identifier.urihttp://repositorio.ipen.br/handle/123456789/30584
dc.localRio de Janeiropt_BR
dc.local.eventoSantos, SPpt_BR
dc.publisherAssociação Brasileira de Energia Nuclear
dc.rightsopenAccesspt_BR
dc.subjectexternal beam radiation therapy
dc.subjectneoplasms
dc.subjectpatients
dc.subjectprostate
dc.subjectradiotherapy
dc.subjectside effects
dc.subjecttoxicity
dc.subjecturinary tract
dc.titleEvaluation of acute toxicity in the treatment of prostate cancer with conformational radiotherapypt_BR
dc.typeTexto completo de eventopt_BR
dspace.entity.typePublication
ipen.autorMARIA ELISA CHUERY MARTINS ROSTELATO
ipen.autorCARLOS ALBERTO ZEITUNI
ipen.autorHIGOR SOUZA CARLECH
ipen.codigoautor7
ipen.codigoautor944
ipen.codigoautor14691
ipen.contributor.ipenauthorMARIA ELISA CHUERY MARTINS ROSTELATO
ipen.contributor.ipenauthorCARLOS ALBERTO ZEITUNI
ipen.contributor.ipenauthorHIGOR SOUZA CARLECH
ipen.date.recebimento20-01
ipen.event.datapadronizada2019pt_BR
ipen.identifier.ipendoc26234pt_BR
ipen.notas.internasProceedingspt_BR
ipen.subtitulochoort with 45 patientspt_BR
ipen.type.genreArtigo
relation.isAuthorOfPublicationda77b491-04ff-4c68-aa65-dead9208a48c
relation.isAuthorOfPublication02421b96-adef-4759-b25e-67d4759aa676
relation.isAuthorOfPublication17fb8507-69f2-4325-846f-5ec8120856fb
relation.isAuthorOfPublication.latestForDiscovery17fb8507-69f2-4325-846f-5ec8120856fb
sigepi.autor.atividadeROSTELATO, MARIA E.C.M.:7:230:Npt_BR
sigepi.autor.atividadeZEITUNI, CARLOS A.:944:230:Npt_BR
sigepi.autor.atividadeCARLECH, HIGOR S.:14691:230:Spt_BR
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
26234.pdf
Tamanho:
333.74 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar
Coleções
Eventos